Because the incidence of ALK rearrangement is low in unselected NSCLC patients (2–5%) [6]–[14], it is necessary to elucidate clinicopathological and molecular characteristics of ALK-positive lung cancer to improve screening efficiency. This evidence concerns the gene ALK and lung cancer.